Phase 1 study of azacitidine in combination with quizartinib in patients with FLT3 or CBL mutated MDS and MDS/MPN-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Phase 1 study of azacitidine in combination with quizartinib in patients with FLT3 or CBL mutated MDS and MDS/MPN

Published:2024-07 Issue: Volume:142 Page:107518
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Montalban-Bravo Guillermo,Jabbour Elias,Chien Kelly,Hammond Danielle,Short Nicholas,Ravandi Farhad,Konopleva Marina,Borthakur Gautam,Daver Naval,Kanagal-Shammana Rashmi,Loghavi Sanam,Qiao Wei,Huang Xuelin,Schneider Heather,Meyer Meghan,Kantarjian Hagop,Garcia-Manero Guillermo

Publisher

Elsevier BV

Reference46 articles.

1. International scoring system for evaluating prognosis in myelodysplastic syndromes;Greenberg;Blood,1997

2. Suboptimal response rates to hypomethylating agent therapy in chronic myelomonocytic leukemia; a single institutional study of 121 patients;Coston;Am. J. Hematol.,2019

3. Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents;Alfonso;Am. J. Hematol.,2017

4. Hypomethylating agents (HMAs) effect on myelodysplastic/myeloproliferative neoplasm unclassifiable (MDS/MPN-U): single institution experience;Al-Kali;Leuk. Lymphoma,2018

5. Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN;Jabbour;Blood,2017

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP